Danaher Stock

$205.72

2.98% today

NYSE, Aug 12, 10:05 pm CET

ISIN

US2358511028

Symbol

DHR

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Overview Dividends Analysts Charts News Strategies

Danaher Stock price

$199.76

+22.47 12.68% 5Y

NYSE, Closing price Mon, Aug 11 2025

-0.80 0.40%

ISIN

US2358511028

Symbol

DHR

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Life Sciences Tools & Services

Key metrics

Basic

Market capitalization

$143.0b

Enterprise Value

$157.4b

Net debt

$14.4b

Cash

$3.0b

Shares outstanding

715.9m

Valuation (TTM | estimate)

P/E

42.1 | 25.7

P/S

6.0 | 5.7

EV/Sales

6.6 | 6.3

EV/FCF

32.4

P/B

2.7

Dividends

DPS

$1.08

Yield 1Y | 5Y

0.5% | 0.4%

Growth 1Y | 5Y

9.2% | 12.4%

Payout 1Y | 3Y

20.4% | 13.9%

Increased

11 Years

Financials (TTM | estimate)

Revenue

$24.0b | $24.9b

EBITDA

$7.1b | $7.7b

EBIT

$4.8b | $7.0b

Net Income

$3.4b | $5.6b

Free Cash Flow

$4.9b

Growth (TTM | estimate)

Revenue

1.9% | 4.5%

EBITDA

-1.8% | 1.5%

EBIT

-6.0% | 35.3%

Net Income

-18.8% | 43.0%

Free Cash Flow

-4.7%

Financial Health

Equity Ratio

63.9%

Return on Equity

7.9%

ROCE

6.4%

ROIC

5.3%

Debt/Equity

0.3

EPS

$4.7

FCF per Share

$6.8

Short interest

1.2%

Employees

62k

Rev per Employee

$390.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

Danaher Stock Analysis

Unlock Scores for Free

??

31 Analysts have issued a Danaher forecast:

28x Buy

90%

More details on Analyst Estimates Including Price Targets

31 Analysts have issued a Danaher forecast:

Buy

90%

Hold

10%

Analyst Estimates with Stock Price Targets

Financial data from Danaher

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	24,013 24,013	2% 2% 100%
- Direct Costs	9,673 9,673	1% 1% 40%
Gross Profit	14,340 14,340	2% 2% 60%
- Selling and Administrative Expenses	7,980 7,980	8% 8% 33%
- Research and Development Expense	1,607 1,607	5% 5% 7%
EBITDA	7,141 7,141	2% 2% 30%
- Depreciation and Amortization	2,388 2,388	8% 8% 10%
EBIT (Operating Income) EBIT	4,753 4,753	6% 6% 20%
Net Profit	3,413 3,413	19% 19% 14%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Danaher Stock News

Neutral

Business Wire

●

about 2 hours ago

EQUITY ALERT: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Danaher Corporation – DHR

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Danaher Corporation (NYSE: DHR). If you currently own shares of Danaher stock, please visit the firm's website at https://rosenlegal.com/submit-form/?case_id=17717 for more information. You may also contact Phillip Ki...

Neutral

PRNewsWire

●

12 days ago

Danaher Appoints Jonathan Leiken as General Counsel

WASHINGTON , July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member...

Positive

The Motley Fool

●

14 days ago

Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever

Often, great investing boils down to holding on to great stocks. It can be as simple as that.

More Danaher News

Company Profile

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Head office	United States
CEO	Rainer Blair
Employees	62,000
Founded	1984
Website	www.danaher.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now